Differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression

International Journal of Oncology

Volumn 33, Issue 6, 2008, Pages 1299-1306

  Song, Ju Dong ^a,c   Kim, Kang Mi ^a   Kim, Koan Hoi ^a   Kim, Chi Dae ^a,b   Kim, Jong Min ^c   Yoo, Young Hyun ^c   Park, Young Chul ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University   (South Korea)

^c Dong A University   (South Korea)

Author keywords

Cell cycle; Cyclin D1; Diphenyleneiodonium; ERK activation; p53

Indexed keywords

CYCLIN D1; DIPHENYLIODONIUM SALT; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; CATION; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENZYME INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TP53 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION; CELL CYCLE; CELL STRAIN HCT116; CELL STRAIN HL 60; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME;

CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HCT116 CELLS; HL-60 CELLS; HUMANS; NADPH OXIDASE; NEOPLASMS; ONIUM COMPOUNDS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 59049093808     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000121     Document Type: Article

References (44)

1. Cross AR and Jones OT: The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils. Specific labelling of a component polypeptide of the oxidase. Biochem J 237: 111-116, 1986.
2. O'Donnell BV, Tew DG, Jones OT and England PJ: Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. Biochem J 290: 41-49, 1993.
3. Stuehr DJ, Fasehun OA, Kwon NS, Gross SS, Gonzalez JA, Levi R and Nathan CF: Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J 5: 98-103, 1991.
4. Tew DG: Inhibition of cytochrome P450 reductase by the diphenyliodonium cation. Kinetic analysis and covalent modifications. Biochemistry 32: 10209-10215, 1993.
5. Coves J, Lebrun C, Gervasi G, Dalbon P and Fontecave M: Overexpression of the FAD-binding domain of the sulphite reductase flavoprotein component from Esherichia coli and its inhibition by iodonium diphenylchloride. Biochem J 342: 465-472, 1999.
6. Chakraborty S and Massey V: Reaction of reduced flavins and flavoproteins with diphenyliodonium chloride. J Biol Chem 277: 41507-41516, 2002.
7. Sanders SA, Eisenthal R and Harrison R: NADH oxidase activity of human xanthine oxidoreductase-generation of superoxide anion. Eur J Biochem 245: 541-548, 1997.
8. O'Donnell VB, Smith GC and Jones OT: Involvement of phenyl radicals in iodonium inhibition of flavoenzymes. Mol Pharmacol 46: 778-785, 1994.
9. Doussiere J, Gaillard J and Vignais PV: The heme component of the neutrophil NADPH oxidase complex is a target for aryliodonium compounds. Biochemistry 38: 3694-3703, 1999.
10. Li Y and Trush MA: Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem Biophys Res Commun 18: 295-299, 1998.
11. Pandian RP, Kutala VK, Liaugminas A, Parinandi NL and Kuppusamy P: Lipopolysaccharide-induced alterations in oxygen consumption and radical generation in endothelial cells. Mol Cell Biochem 278: 119-127, 2005.
12. Joneson T and Bar-Sagi DA: Rac1 effector site controlling mitogenesis through superoxide production. J Biol Chem 273: 17992-17994, 1998.
13. Finkel T and Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Nature 408: 239-247, 2000.
14. Burch PM, Yuan Z, Loonen A and Heintz NH: An extracellular signal-regulated kinase 1- and 2-dependent program of chromatin trafficking of c-Fos and Fra-1 is required for cyclin D1 expression during cell cycle reentry. Mol Cell Biol 24: 4696-4709, 2004.
15. Yuan Z, Schellekens H, Warner L, Janssen-Heininger Y, Burch P and Heintz NH: Reactive nitrogen species block cell cycle re-entry through sustained production of hydrogen peroxide. Am J Respir Cell Mol Biol 28: 705-712, 2003.
16. Ranjan P, Anathy V, Burch PM, Weirather K, Lambeth JD and Heintz NH: Redox-dependent expression of cyclin D1 and cell proliferation by Nox1 in mouse lung epithelial cells. Antioxid Redox Signal 8: 1447-1459, 2006.
17. Scaife RM: G2 cell cycle arrest, down-regulation of cyclin B, and induction of mitotic catastrophe by the flavoprotein inhibitor diphenyleneiodonium. Mol Cancer Ther 3: 1229-1237, 2004.
18. Park SE, Song JD, Kim KM, Park YM, Kim ND, Yoo YH and Park YC: Diphenyleneiodonium induces ROS-independent p53 expression and apoptosis in human RPE cells. FEBS Lett 581: 180-186, 2007.
19. White AE, Livanos EM and Tlsty TD: Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 8: 666-677, 1994.
20. Amundson SA, Myers TG and Fornace AJ Jr: Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. Oncogene 17: 3287-3299, 1998.
21. Vousden KH: p53: death star. Cell 103: 691-694, 2000.
22. 1-phase progression. Genes Dev 13: 1501-1512, 1999.
23. Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW and Aaronson SA: p21Waf1/ Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 18: 2789-2797, 1999.
24. 1 to S phase of the cell cycle in normal human diploid fibroblasts. Radiat Phys Chem 72: 315-321, 2005.
25. Lam EW and Watson RJ: An E2F-binding site mediates cell-cycle regulated repression of mouse B-myb transcription. EMBO J 12: 2705-2713, 1993.
26. Jo HJ, Song JD, Kim KM, Cho YH, Kim KH and Park YC: Diallyl disulfide induces reversible G2/M phase arrest on a p53-independent mechanism in human colon cancer HCT-116 cells. Oncol Rep 19: 275-280, 2008.
27. 2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96: 3706-3711, 1999.
28. Balcerczyk A, Soszynski M, Rybaczek D, Przygodzki T, Karowicz-Bilinska A, Maszewski J and Bartosz G: Induction of apoptosis and modulation of production of reactive oxygen species in human endothelial cells by diphenyleneiodonium. Biochem Pharmacol 69: 1263-1273, 2005.
29. Riganti C, Gazzano E, Polimeni M, Costamagna C, Bosia A and Ghigo D: Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem 279: 47726-47731, 2004.
30. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA and Robinson JP: DPI induces mitochondrial superoxide-mediated apoptosis. Free Radic Biol Med 34: 465-477, 2003.
31. Draetta GF: Mammalian G1 cyclins. Curr Opin Cell Biol 6: 842-846, 1994.
32. Sherr CJ: D-type cyclins. Trends Biochem Sci 20: 187-190, 1995.
33. Brar SS, Corbin Z, Kennedy TP, Hemendinger R, Thomton L, Bommarius B, Arnold RS, Whorton AR, Sturrock AB, Huecksteadt TP, Quinn MT, Krenitsky K, Ardie KG, Lambeth JD and Hoidal JR: NOX5 NAD(P)H oxidase regulates growth and apoptosis in DU 145 prostate cancer cell. Am J Physiol Cell Physiol 285: C353-C369, 2003.
34. Scaife RM: Selective and irreversible cell cycle inhibition by diphenyleneiodonium. Mol Cancer Ther 4: 876-884, 2005.
35. Stewart ZA, Westfall MD and Pietenpol JA: Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 24: 139-145, 2003.
36. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
37. Sankala HM, Hait NC, Paugh SW, Shida D, Lépine S, Elmore LW, Dent P, Milstien S and Spiegel S: Involvement of sphingosine kinase 2 in p53-independent induction of p21 by the chemotherapeutic drug doxorubicin. Cancer Res 67: 10466-10474, 2007.
38. Huo JX, Metz SA and Li GD: p53-independent induction of p21(waf1/cip1) contributes to the activation of caspases in GTP-depletion-induced apoptosis of insulin-secreting cells. Cell Death Differ 11: 99-109, 2004.
39. Chen L, Yu LJ and Waxman DJ: Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 57: 4830-4837, 1997.
40. Wever RM, van Dam T, van Rijn HJ, de Groot F and Rabelink TJ: Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun 237: 340-344, 1997.
41. Burch PM and Heintz NH: Redox regulation of cell-cycle reentry: cyclin D1 as a primary target for the mitogenic effects of reactive oxygen and nitrogen species. Antioxid Redox Signal 7: 741-751, 2005.
42. Ciccarelli C, Marampon F, Scoglio A, Mauro A, Giacinti C, De Cesaris P and Zani BM: p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells. Mol Cancer 4: 41, 2005.
43. Todd DE, Densham RM, Molton SA, Balmanno K, Newson C, Weston CR, Garner AP, Scott L and Cook SJ: ERK1/2 and p38 cooperate to induce a p21CIPI-dependent G1 cell cycle arrest. Oncogene 23: 3284-3295, 2004.
44. Huang S and Ingber DE: A discrete cell cycle checkpoint in late G(1) that is cytoskeleton-dependent and MAP kinase (Erk)-independent. Exp Cell Res 275: 255-264, 2002.